BDRX · NASDAQ

Biodexa Pharmaceuticals (BDRX) Stock Price & Fundamentals

$280.68−1.10%−$3.11End-of-day price as of Oct 9, 2026

Sample prices

Prices on this page are generated sample data for development, not real market data, so market cap, P/E and dividend yield are illustrative too. Fundamentals are real, from Biodexa Pharmaceuticals's SEC filings.

Biodexa Pharmaceuticals (BDRX) closed at $280.68 on Oct 9, 2026, down 1.10% from the previous close of $283.79.

Share price, past year

1Y −1.30%

Daily closing prices

52-week range $271.45 – $324.28.

Monthly closing prices

Last closing price of each month
Date	Close
Oct 9, 2026	$280.68
Sep 30, 2026	$275.94
Aug 31, 2026	$280.58
Jul 31, 2026	$300.32
Jun 30, 2026	$292.16
May 29, 2026	$304.09
Apr 30, 2026	$311.73
Mar 31, 2026	$302.54
Feb 27, 2026	$303.32
Jan 30, 2026	$303.31
Dec 31, 2025	$297.12
Nov 28, 2025	$301.90
Oct 31, 2025	$289.15

Key statistics

Market cap: —
P/E (TTM): —
EPS (TTM): —
Revenue (TTM): —
Net income (TTM): —
Shares outstanding: 225.8B
Dividend yield: —
52-week range: $271.45 – $324.28

Market cap, P/E and dividend yield aren't shown for Biodexa Pharmaceuticals yet: its SEC filings count its ordinary shares, which can differ from the shares traded in the US, and report in British pounds.

Financials

Biodexa Pharmaceuticals reported revenue of £381.00K for fiscal 2023, down 45.49% from fiscal 2022.

Figures are in British pounds (GBP), as Biodexa Pharmaceuticals reports them to the SEC.

Annual revenue

FY15FY16FY17FY18FY19FY20FY21FY22FY23

Biodexa Pharmaceuticals annual financials by fiscal year, from SEC filings
Fiscal year	Revenue	Growth	Net income	Net margin	EPS (diluted)	Free cash flow
FY2023ended Dec 31, 2023	£381.00K	−45.5%	—	—	−£0.02	−£6.85M
FY2022ended Dec 31, 2022	£699.00K	+20.9%	—	—	−£1.55	−£7.11M
FY2021ended Dec 31, 2021	£578.00K	+68.5%	—	—	—	−£6.33M
FY2020ended Dec 31, 2020	£343.00K	−49.1%	—	—	—	−£9.51M
FY2019ended Dec 31, 2019	£674.00K	−65.2%	—	—	—	−£6.80M
FY2018ended Dec 31, 2018	£1.94M	+96.0%	—	—	—	−£13.69M
FY2017ended Dec 31, 2017	£989.00K	−25.3%	—	—	—	−£13.66M
FY2016ended Dec 31, 2016	£1.32M	−3.8%	—	—	—	−£14.43M
FY2015ended Dec 31, 2015	£1.38M	—	—	—	—	—

Company profile

Name: Biodexa Pharmaceuticals Plc
Ticker: BDRX
Exchange: NASDAQ
Industry (SEC SIC): Pharmaceutical Preparations
Headquarters: 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ
Incorporated in: X0
Fiscal year ends: December
SEC CIK: 0001643918

Recent SEC filings

20-FAnnual report for period ending Dec 31, 2025
Mar 27, 2026
20-FAnnual report for period ending Dec 31, 2024
Apr 11, 2025
20-FAnnual report for period ending Dec 31, 2023
Apr 19, 2024
20-F/AAnnual report for period ending Dec 31, 2022
May 5, 2023
20-FAnnual report for period ending Dec 31, 2022
Apr 28, 2023
20-FAnnual report for period ending Dec 31, 2021
Apr 26, 2022
20-FAnnual report for period ending Dec 31, 2020
Apr 30, 2021
20-F/AAnnual report for period ending Dec 31, 2019
Jun 17, 2020

Frequently asked questions

What is Biodexa Pharmaceuticals's stock price?

Biodexa Pharmaceuticals (BDRX) closed at $280.68 on Oct 9, 2026, down 1.10% from the previous close of $283.79.

How much revenue does Biodexa Pharmaceuticals make?

Biodexa Pharmaceuticals reported revenue of £381.00K for fiscal 2023, down 45.49% from fiscal 2022.

Sources and methodology

Fundamentals come from Biodexa Pharmaceuticals Plc's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures